Transplantation osteoporosis

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 6, 2001, Pages 283-290

  Cohen, A ^a   Shane, E ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CYCLOSPORIN; ESTROGEN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; RALOXIFENE; SEX HORMONE; TACROLIMUS; VITAMIN D DERIVATIVE;

BONE ATROPHY; CLINICAL FEATURE; FRACTURE; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

EID: 0035217181     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200112000-00004     Document Type: Review

References (151)

1. The registry of the International Society for Heart Lung Transplantation: Sixteenth official report-1999
2. Transplantation osteoporosis
3. Increased risk of fracture in patients receiving solid organ transplants
4. Bone turnover in transplantation osteoporosis
5. Osteoporosis after organ transplantation
6. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study
7. Glucocorticoid-induced osteoporosis
8. Use of oral corticosteroids and risk of fractures
9. The science and therapy of glucocorticoid-induced bone loss
10. New developments in the pathogenesis and treatment of steroid-induced osteoporosis
11. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone
12. Bone histomorphometry in glucocorticoid-induced osteoporosis
13. Stimulation of osteoprotegrin ligand and inhibition of osteoprotegrin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid induced osteoporosis
14. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
15. Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics
16. Effect of cortisone treatment on the active transport of calcium by the small intestine
17. Glucocorticoid-induced osteoporosis
18. Cyclosporine
19. Renal transplantation
20. Post-transplantation bone disease: The role of immunosuppressive agents on the skeleton
21. The effects of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat
22. Cyclosporin A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration
23. Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption
24. The role of testosterone in cyclosporine-induced osteopenia
25. Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat
26. 17 Beta estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin A
27. Raloxifene analog (Ly 117018-HCL) ameliorates cyclosporin A induced osteopenia
28. Salmon calcitonin prevents cyclosporin A induced high turnover bone loss
29. Alendronate prevents cyclosporin-induced osteopenia in the rat
30. Osteoporosis after organ transplantation
31. The deleterious effects of long term cyclosporin A, cyclosporin G and FK506 on bone mineral metabolism in vivo
32. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats
33. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression
34. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine
35. Osteoporosis after organ transplantation
36. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A
37. Azathioprine alone is bone sparing and does not alter cyclosporine A induced osteopenia in the rat
38. Mycophenolate mofetil: A promising new immunosuppressant that does not cause bone loss in the rat
39. Rapamycin: A bone sparing irnmunosuppressant?
40. Prevalence and risks factors for osteopoenia in dialysis patients
41. Risk factors for reduced bone density in haemodialysis patients
42. Bone mineral densitometry in dialyzed patients: Quantitative computed tomography versus dual photon absorptiometry
43. Risk factors for vertebral fractures in renal osteodystrophy
44. Increased risk of hip fracture in U.S. Medicare end-stage renal disease patients
45. Bone disease in patients with longterm renal transplantation and normal renal function
46. Continuing loss of vertebral mineral density in renal transplant recipients
47. Long-term bone loss in kidney transplant recipients: Across-sectional and longitudinal study
48. Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation
49. Factors influencing vertebral bone density after renal transplantation
50. Renal transplantation and osteoporosis
51. Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease
52. Rapid loss of vertebral bone density after renal transplantation
53. Factors involved in the loss of bone mineral density after renal transplantation
54. Changes of bone metabolism indices in patients receiving immunosuppressive therapy including low doses of steroids after transplantation
55. Changes in bone mass early after kidney transplantation
56. Loss of regional bone mineral density in the first 12 months following renal transplantation
57. Bone mineral density after renal transplantation: Long-term follow-up
58. Fracture frequency after kidney transplantation
59. Analysis of fracture prevalence in kidney-pancreas allograft recipients
60. Increased fracture rate in diabetes mellitus and females after renal transplantation
61. Posttransplant bone disease: Evidence for a high bone resorption state
62. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation
63. Bone loss in long term renal transplantation: Histopathology and densitometry analysis
64. Osteoporosis and bone morbidity in cardiac transplant recipients
65. Loss of vertebral bone density in heart transplant patients
66. Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure
67. Osteoporosis after cardiac transplantation
68. Bone loss and turnover after cardiac transplantation
69. Bone loss after cardiac transplantation: A prospective study
70. A prospective study of bone loss and turnover after cardiac transplantation: Effect of calcium supplementation with or without calcitonin
71. Cyclosporine induces high turnover and may contribute to bone loss after heart transplantation
72. Osteoporosis in heart transplant recipients: A longitudinal study
73. Timing and quantification of bone loss in cardiac transplant recipients
74. Bone mineral loss and recovery after cardiac transplantation
75. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients
76. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry
77. Fracture after cardiac transplantation: A prospective longitudinal study
78. Mechanism of bone loss after cardiac transplantation
79. Bone disease in patients with primary biliary cirrhosis
80. Bone loss and reduced osteoblast function in primary biliary cirrhosis
81. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice
82. Ethanol inhibits human bone cell proliferation and function in vitro
83. Alcohol-induced bone disease
84. Vertebral fractures and osteopenia in chronic alcoholic patients
85. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation
86. Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or other factors?
87. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy
88. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis
89. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease
90. Osteoporosis and bone mineral metabolism in cirrhotic patients referred for liver transplantation
91. Bone disease after liver transplantation
92. Bone disease after liver transplantation
93. Bone loss after liver transplantation
94. Bone fractures in liver transplant patients
95. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis
96. Bone loss after orthotopic liver transplantation
97. Bone loss at the proximal femur and reduced lean mass following liver transplantation: A longitudinal study
98. Bone mineral density in the long term after liver transplantation
99. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation
100. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation
101. Long-term persistence of low bone density in orthotopic liver transplantation
102. Bone loss and turnover in patients with liver transplantation
103. Calcitonin and bisphosphonate treatment in bone loss after liver transplantation
104. Early increase in plasma parathyroid hormone level following liver transplantation
105. Bone mineral status in end-stage liver disease and the effect of liver transplantation
106. Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with cyclosporin
107. Mechanism of bone loss after liver transplantation: A histomorphometric analysis
108. Osteoporosis in patients with cystic fibrosis
109. Severe osteoporosis before and after lung transplantation
110. Increased rate of fractures and severe kyphosis: Sequelae of living into adulthood with cystic fibrosis
111. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease
112. Osteoporosis in lung transplantation candidates with end stage pulmonary disease
113. Bone mineral density in lung-transplant recipients before and after graft: Prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate
114. Osteoporosis in patients undergoing lung transplantation
115. Osteoporosis and lung transplantation: A prospective study
116. Bone loss and fracture after lung transplantation
117. High turnover bone disease following lung transplantation
118. Bone histomorphometry in adult patients with cystic fibrosis
119. Renal osteodystrophy in adults and children
120. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis The Alendronate Phase III Osteoporosis Treatment Study Group
121. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
122. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
123. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
124. Risedronate therapy prevents corticosteroid-induced bone loss
125. Treatment of established bone loss after renal transplantation with etidronate
126. Efficacy of pamidronate for osteoporosis in cystic fibrosis patients following lung transplantation
127. Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate
128. Pamidronate therapy as prevention of bone loss following renal transplantation
129. Prevention of bone loss in kidney graft recipients
130. Prevention of bone loss after heart transplantation with antiresorptive therapy: A pilot study
131. Intravenous pamidronate as a treatment for osteoporosis after heart transplantation: A prospective study
132. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation
133. Prevention of bone loss in cardiac transplant recipients: A comparison of biphosphonates and vitamin D
134. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alpha calcidiol
135. Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation
136. Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation
137. Immunomodulatory role of 1,25 Dihydroxyvitamin D3
138. Dihydroxy-24-oxo-16-ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo
139. Effects of calcium, calcidiol, and monofluorophosphate on lumbar bone mass and parathyroid function in patients after cardiac transplantation
140. Calcitonin, editronate and calcidiol treatment in bone loss after cardiac transplantation
141. Effect of calcitriol on bone loss after cardiac or lung transplantation
142. Calcitriol in prevention and therapy of osteoporosis after liver transplantation
143. Efficiency of preventive treatment for osteoporosis after renal transplantation
144. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation
145. Prevention of osteoporosis after cardiac transplantation: A prospective, longitudinal, randomized, double-blind trial with calcitriol
146. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin
147. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
148. Progression of steroid-associated osteoporosis after heart transplantation
149. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation
150. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis: A 2-year follow-up study